← Leaderboards
Jonathan Stuart Serody
Univ Of North Carolina Chapel Hill
$17,391,591
Attributed
$18,475,090
Total exposure
26
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,475,090 · 26
By mechanism
R01$11,450,976 · 6
T32$2,687,856 · 2
P50$1,960,008 · 5
R21$1,093,049 · 2
R56$792,408 · 2
P30$380,357 · 3
Top collaborators
- Nelson J. Chao5 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Carla Maria Pedrosa Ribeiro$2,769,732
- Leshara Malika Fulton$63,897
- Stephen Vernon Frye$8,267,632
- Gianpietro Dotti$17,018,250
- Chad V Pecot$5,843,920
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteMediatingCellsCytokineMalignant - DescriptorImmuneTumorResearch PersonnelBiologyInflammatoryGenerationsClinical TrialsGrantAllogenicResponseStem Cell TransplantNovel StrategiesPathogenesisPlayChemotherapyMalignant NeoplasmsRegulatory T-LymphocyteImmunotherapyImmune Response
Grant awards (74)
UNC Immunotherapy Training Grant (IM-TAG)$174,118
T32 · FY2025 · CA · contact PI
SToP Cancer SPORE: Career Enhancement Program$89,609
P50 · FY2025 · CA · contact PI
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.$679,845
R01 · FY2024 · HL · contact PI
UNC Immunotherapy Training Grant (IM-TAG)$181,622
T32 · FY2024 · CA · contact PI
SToP Cancer SPORE: Career Enhancement Program$86,019
P50 · FY2024 · CA · contact PI
Immunology Research Program$41,357
P30 · FY2024 · CA · contact PI
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.$693,720
R01 · FY2023 · HL · contact PI
UNC Immunotherapy Training Grant (IM-TAG)$165,117
T32 · FY2023 · CA · contact PI
SToP Cancer SPORE: Career Enhancement Program$84,825
P50 · FY2023 · CA · contact PI
Immunology Research Program$45,950
P30 · FY2023 · CA · contact PI
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.$655,949
R01 · FY2022 · HL · contact PI
SToP Cancer SPORE: Career Enhancement Program$84,847
P50 · FY2022 · CA · contact PI
Immunology Research Program$45,950
P30 · FY2022 · CA · contact PI
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.$655,949
R01 · FY2021 · HL · contact PI
Duke-UNC Chapel Hill Immunotherapy Training Grant$459,827
T32 · FY2021 · CA · contact PI
Immunology Research Program$45,950
P30 · FY2021 · CA · contact PI
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD$543,763
R01 · FY2020 · HL · contact PI
Duke-UNC Chapel Hill Immunotherapy Training Grant$311,363
T32 · FY2020 · CA · contact PI
Immunology Research Program (Program 2)$39,439
P30 · FY2020 · CA · contact PI
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD$543,763
R01 · FY2019 · HL · contact PI
Duke-UNC Chapel Hill Immunotherapy Training Grant$475,705
T32 · FY2019 · CA · contact PI
Immunology Research Program (Program 2)$38,227
P30 · FY2019 · CA · contact PI
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD$543,763
R01 · FY2018 · HL · contact PI
Duke-UNC Chapel Hill Immunotherapy Training Grant$449,807
T32 · FY2018 · CA · contact PI
Immunology Research Program (Program 2)$39,437
P30 · FY2018 · CA · contact PI
Immunology Research Program (Program 2)$2,968
P30 · FY2018 · CA · contact PI
Immunology Research Program (Program 2)$2,101
P30 · FY2018 · CA · contact PI
Immunology Research Program (Program 2)$1,366
P30 · FY2018 · CA · contact PI
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD$543,763
R01 · FY2017 · HL · contact PI
Duke-UNC Chapel Hill Immunotherapy Training Grant$470,297
T32 · FY2017 · CA · contact PI
Immunology Research Program (Program 2)$38,689
P30 · FY2017 · CA · contact PI
Th1/Th17 Macrophage Interactions in Cutaneous GVHD$309,342
R01 · FY2016 · CA · contact PI
Immunology Research Program (Program 2)$38,923
P30 · FY2016 · CA · contact PI
Targeting CCR7 for the Prevention/Treatment of GvHD$364,450
R01 · FY2015 · HL · contact PI
Th1/Th17 Macrophage Interactions in Cutaneous GVHD$309,342
R01 · FY2015 · CA · contact PI
Targeting CCR7 for the Prevention/Treatment of GvHD$362,600
R01 · FY2014 · HL · contact PI
Th1/Th17 Macrophage Interactions in Cutaneous GVHD$300,062
R01 · FY2014 · CA · contact PI
Targeting the Infiltrating Immune Cells in Claudin-low and Basal-type Tumors$182,145
P50 · FY2014 · CA · contact PI
Targeting CCR7 for the Prevention/Treatment of GvHD$352,240
R01 · FY2013 · HL · contact PI
Th1/Th17 Macrophage Interactions in Cutaneous GVHD$290,781
R01 · FY2013 · CA · contact PI
Targeting the Infiltrating Immune Cells in Claudin-low and Basal-type Tumors$181,318
P50 · FY2013 · CA · contact PI
Targeting CCR7 for the Prevention/Treatment of GvHD$370,000
R01 · FY2012 · HL · contact PI
Th1/Th17 Macrophage Interactions in Cutaneous GVHD$309,342
R01 · FY2012 · CA · contact PI
Targeting the Infiltrating Immune Cells in Claudin-low and Basal-type Tumors$210,435
P50 · FY2012 · CA · contact PI
Treg Migration in GVHD$420,446
R56 · FY2011 · AI · contact PI
Modeling TH17 Cells in Acute GVHD$371,962
R56 · FY2010 · AI · contact PI
Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors$223,540
P50 · FY2010 · CA · contact PI
Treg Migration in GVHD$396,959
R01 · FY2009 · AI · contact PI
Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors$223,827
P50 · FY2009 · CA · contact PI
Treg Migration in GVHD$136,719
R01 · FY2009 · AI · contact PI
Treg Migration in GVHD$387,126
R01 · FY2008 · AI · contact PI
Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors$224,073
P50 · FY2008 · CA · contact PI
CLINICAL TRIAL: LCCC 0418: PHASE I/II MULTIEPTITOPE DENDRITIC CELL VACCINE IN B$2,678
M01 · FY2008 · RR · contact PI
Treg Migration in GVHD$383,457
R01 · FY2007 · AI · contact PI
Mechanisms Involved in T cell trafficking in GVHD$306,862
R01 · FY2007 · CA · contact PI
Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors$218,703
P50 · FY2007 · CA · contact PI
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE$5,252
M01 · FY2007 · RR · contact PI
LCCC 0418: PHASE I/II MULTIEPTITOPE DENDRITIC CELL VACCINE IN BREAST CANCER$1,876
M01 · FY2007 · RR · contact PI
Treg Migration in GVHD$383,411
R01 · FY2006 · AI · contact PI
Mechanisms Involved in T cell trafficking in GVHD$316,027
R01 · FY2006 · CA · contact PI
Multimodality Therapy for Metastatic Breast Cancer$281,574
R21 · FY2006 · CA · contact PI
Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors$150,667
P50 · FY2006 · CA · contact PI
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE$8,673
M01 · FY2006 · RR · contact PI
Treg Migration in GVHD$340,845
R01 · FY2005 · AI
Mechanisms Involved in T cell trafficking in GVHD$323,632
R01 · FY2005 · CA
Multimodality Therapy for Metastatic Breast Cancer$288,350
R21 · FY2005 · CA
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE$5,655
M01 · FY2005 · RR
Mechanisms Involved in T cell trafficking in GVHD$323,632
R01 · FY2004 · CA
Mechanisms Involved in T cell trafficking in GVHD$323,632
R01 · FY2003 · CA
ENHANCING A BREAST CANCER VACCINE$0
P50 · FY2002 · CA
IMMUNOTHERAPY FOR METASTATIC BREAST CANCER$261,900
R21 · FY2001 · CA
ENHANCING A BREAST CANCER VACCINE$0
P50 · FY2001 · CA
IMMUNOTHERAPY FOR METASTATIC BREAST CANCER$261,225
R21 · FY2000 · CA
ID OF EPITOPES FROM CML RECOGNIZED BY T CELLS$86,302
K08 · FY2000 · CA